| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Model |
From Elan Pharmaceuticals, South San Francisco, California
Transgenic mice mimicking certain features of Alzheimer’s disease (AD)-pathology, namely amyloid plaques and neurofibrillary tangles, have been developed in an effort to better understand the mechanism leading to the formation of these characteristic cerebral lesions. More recently, these animal models have been widely used to investigate emergent therapies aimed at the reduction of the cerebral amyloid load. Several studies have shown that immunotherapy targeting the amyloid peptide (Aß) is efficacious at clearing the amyloid plaques or preventing their formation, and at reducing the memory/behavior impairment observed in these animals. In AD, different types of plaques likely have different pathogenic significance, and further characterization of plaque pathology in the PDAPP transgenic mice would enhance the evaluation of potential therapeutics. In the present study, a morphological classification of amyloid plaques present in the brains of PDAPP mice was established by using Thioflavin-S staining. Neuritic dystrophy associated with amyloid plaques was also investigated. Finally, the efficacy of passive immunization with anti-Aß antibodies on the clearance of Thio-S positive amyloid plaques was studied. Our results show that distinct morphological types of plaques are differentially cleared depending upon the isotype of the antibody.
This article has been cited by other articles:
 |
|
 |
|
  S. Petratos, Q.-X. Li, A. J. George, X. Hou, M. L. Kerr, S. E. Unabia, I. Hatzinisiriou, D. Maksel, M.-I. Aguilar, and D. H. Small The -amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism Brain, January 1, 2008; 131(1): 90 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Levites, L. A. Smithson, R. W. Price, R. S. Dakin, B. Yuan, M. R. Sierks, J. Kim, E. McGowan, D. K. Reed, T. L. Rosenberry, et al. Insights into the mechanisms of action of anti-A{beta} antibodies in Alzheimer's disease mouse models FASEB J, December 1, 2006; 20(14): 2576 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang Therapeutic approaches to Alzheimer's disease Brain, November 1, 2006; 129(11): 2840 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Devi, B. M. Prabhu, D. F. Galati, N. G. Avadhani, and H. K. Anandatheerthavarada Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci., August 30, 2006; 26(35): 9057 - 9068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Lee, L. Z. Leng, B. Zhang, L. Kwong, J. Q. Trojanowski, T. Abel, and V. M.-Y. Lee Targeting Amyloid-beta Peptide (Abeta) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Abeta Precursor Protein (APP) Transgenic Mice J. Biol. Chem., February 17, 2006; 281(7): 4292 - 4299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Koldamova, M. Staufenbiel, and I. Lefterov Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice J. Biol. Chem., December 30, 2005; 280(52): 43224 - 43235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Buttini, E. Masliah, R. Barbour, H. Grajeda, R. Motter, K. Johnson-Wood, K. Khan, P. Seubert, S. Freedman, D. Schenk, et al. {beta}-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease J. Neurosci., October 5, 2005; 25(40): 9096 - 9101. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
